Targeting XIAP for the treatment of malignancy |
| |
Authors: | Schimmer A D Dalili S Batey R A Riedl S J |
| |
Institution: | The Ontario Cancer Institute, Toronto, Ontario, Canada. aaron.schimmer@utoronto.ca |
| |
Abstract: | X-linked inhibitor of apoptosis protein (XIAP) is a member of the inhibitor of apoptosis proteins family of caspase inhibitors that selectively binds and inhibits caspases-3, -7 and -9, but not caspase-8. As such, XIAP blocks a substantial portion of the apoptosis pathway and is an attractive target for novel therapeutic agents for the treatment of malignancy. Antisense oligonucleotides directed against XIAP are effective in vitro and are currently being evaluated in clinical trials. Small molecule XIAP inhibitors that target the baculovirus IAP repeat (BIR) 2 or BIR 3 domain are in preclinical development and are advancing toward the clinic. This review will discuss the progress being made in developing antisense and small-molecule XIAP inhibitors. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|